{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:17Z","timestamp":1790916797046,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":207,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101340","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:14:31Z","timestamp":1785510871000},"page":"101340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Activation of the PI3K\/AKT\/mTOR signaling pathway in bladder cancer pathogenesis and its therapeutic significance"],"prefix":"10.1016","volume":"48","author":[{"given":"Dereje E.","family":"Bogale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0002","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101340_bib0003","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3390\/ijms21176072","article-title":"Mutational Landscape and Environmental Effects in Bladder Cancer","volume":"21","author":"Hayashi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101340_bib0004","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/medicina57080749","article-title":"Bladder Cancer: Current Challenges and Future Directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0007","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctarc.2026.101340_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0009","doi-asserted-by":"crossref","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101340_bib0011","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/cells13171500","article-title":"PI3K\/AKT\/mTOR Signaling Network in Human Health and Diseases","volume":"13","author":"Omolekan","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0012","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101340_bib0014","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/1947601911407325","article-title":"PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control","volume":"1","author":"Georgescu","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ctarc.2026.101340_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","article-title":"PI3K signaling in cancer: beyond AKT","volume":"45","author":"Lien","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"35","key":"10.1016\/j.ctarc.2026.101340_bib0016","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1200\/JCO.2011.37.4751","article-title":"Regulation, role, and targeting of Akt in cancer","volume":"29","author":"Davies","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctarc.2026.101340_bib0017","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/0008-5472.CAN-09-0975","article-title":"Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0018","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/cancers14061555","article-title":"Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy","volume":"14","author":"Huan","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0019","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.ctarc.2026.101340_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","article-title":"Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers","volume":"145","author":"Hou\u00e9d\u00e9","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101340_bib0021","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/ijc.28518","article-title":"PI3K\/AKT pathway activation in bladder carcinogenesis","volume":"134","author":"Calderaro","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctarc.2026.101340_bib0022","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Bladder Cancer","volume":"1655","author":"Sathe","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ctarc.2026.101340_bib0023","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-016-2570-0","article-title":"PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma","volume":"16","author":"Ross","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124711","article-title":"Somatic Copy Number Abnormalities and Mutations in PI3K\/AKT\/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors","volume":"10","author":"Bellmunt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2026.101340_bib0025","first-page":"641","article-title":"Landscape of targeted therapies for advanced urothelial carcinoma","volume":"5","author":"Shang","year":"2024"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156800908784293659","article-title":"The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications","volume":"8","author":"Carnero","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0027","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0028","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0029","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A Pan-Cancer Proteogenomic Atlas of PI3K\/AKT\/mTOR Pathway Alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0031","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.molcel.2018.08.005","article-title":"Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease","volume":"71","author":"Burke","year":"2018","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101340_bib0032","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctarc.2026.101340_bib0033","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbior.2015.05.002","article-title":"Class I PI 3-kinases: Function and evolution","volume":"59","author":"Kriplani","year":"2015","journal-title":"Adv Biol Regul"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0034","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2443","article-title":"Structural comparisons of class I phosphoinositide 3-kinases","volume":"8","author":"Amzel","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctarc.2026.101340_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ctarc.2026.101340_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT Pathway as a Target for Cancer Treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0037","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-022-00860-9","article-title":"Akt: a key transducer in cancer","volume":"29","author":"Tsai","year":"2022","journal-title":"J Biomed Sci"},{"issue":"Pt 2","key":"10.1016\/j.ctarc.2026.101340_bib0039","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/BJ20041140","article-title":"Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors","volume":"385","author":"Barnett","year":"2005","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0040","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bcp.13021","article-title":"AKT in cancer: new molecular insights and advances in drug development","volume":"82","author":"Mundi","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0042","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0043","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0044","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0046","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1742-4658.2012.08537.x","article-title":"Suppression of survival signalling pathways by the phosphatase PHLPP","volume":"280","author":"O'Neill","year":"2013","journal-title":"FEBS J"},{"issue":"39","key":"10.1016\/j.ctarc.2026.101340_bib0047","doi-asserted-by":"crossref","first-page":"41189","DOI":"10.1074\/jbc.M406731200","article-title":"Identification of a PKB\/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase","volume":"279","author":"Feng","year":"2004","journal-title":"J Biol Chem"},{"issue":"5712","key":"10.1016\/j.ctarc.2026.101340_bib0048","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0049","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/genes11070719","article-title":"PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BCJ20220325","article-title":"The mTORC2 signaling network: targets and cross-talks","volume":"481","author":"Ragupathi","year":"2024","journal-title":"Biochem J"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101340_bib0051","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.3390\/cancers14225520","article-title":"Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy","volume":"14","author":"Bouyahya","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0052","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0053","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/ijms22041743","article-title":"The Role of mTOR Signaling as a Therapeutic Target in Cancer","volume":"22","author":"Popova","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0054","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/genes11091045","article-title":"Regulation of mTORC2 Signaling","volume":"11","author":"Fu","year":"2020","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0056","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cmet.2013.04.010","article-title":"Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2","volume":"17","author":"Humphrey","year":"2013","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0057","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.celrep.2015.07.016","article-title":"A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation","volume":"12","author":"Yang","year":"2015","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0058","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-15-0460","article-title":"PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex","volume":"5","author":"Liu","year":"2015","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101340_bib0059","doi-asserted-by":"crossref","first-page":"10998","DOI":"10.1074\/jbc.M110.195016","article-title":"Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate","volume":"286","author":"Gan","year":"2011","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101340_bib0060","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/bloodadvances.2019001393","article-title":"AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma","volume":"4","author":"Bloedjes","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0061","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1541-7786.MCR-08-0342","article-title":"Akt\/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor","volume":"7","author":"Yoeli-Lerner","year":"2009","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118635","article-title":"Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer","volume":"1867","author":"Evangelisti","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0063","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"FoxO and regulation of apoptosis","volume":"1813","author":"X","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0064","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/cbt.12.4.15954","article-title":"FoxO family members in cancer","volume":"12","author":"Zhang","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0065","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.bbamcr.2011.06.002","article-title":"FoxO transcription factors; Regulation by AKT and 14-3-3 proteins","volume":"1813","author":"Tzivion","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctarc.2026.101340_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.isci.2018.06.006","article-title":"Serine Phosphorylation by mTORC1 Promotes IRS-1 Degradation through SCF\u03b2-TRCP E3 Ubiquitin Ligase","volume":"5","author":"Yoneyama","year":"2018","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0067","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"6035","key":"10.1016\/j.ctarc.2026.101340_bib0068","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0069","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/MCB.00601-09","article-title":"mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling","volume":"30","author":"Julien","year":"2010","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13238-014-0021-8","article-title":"Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity","volume":"5","author":"Liu","year":"2014","journal-title":"Protein Cell"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0071","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ncb2860","article-title":"Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis","volume":"15","author":"Liu","year":"2013","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0072","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol Biomed"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0073","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem Sci"},{"issue":"34","key":"10.1016\/j.ctarc.2026.101340_bib0074","doi-asserted-by":"crossref","first-page":"31099","DOI":"10.1074\/jbc.M111974200","article-title":"Regulation of Raf-Akt Cross-talk","volume":"277","author":"Moelling","year":"2002","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101340_bib0075","doi-asserted-by":"crossref","first-page":"19382","DOI":"10.1074\/jbc.M200732200","article-title":"ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase","volume":"277","author":"Yu","year":"2002","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0076","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/genes12071094","article-title":"The Importance of Being PI3K in the RAS Signaling Network","volume":"12","author":"Cuesta","year":"2021","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0077","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"issue":"37","key":"10.1016\/j.ctarc.2026.101340_bib0078","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0079","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1074\/jbc.M110.159046","article-title":"ERK1\/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1)","volume":"286","author":"Carriere","year":"2011","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0080","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3892\/ijo.2014.2377","article-title":"The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review)","volume":"44","author":"Nakanishi","year":"2014","journal-title":"Int J Oncol"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0081","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0082","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cncr.31921","article-title":"Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities","volume":"125","author":"Millis","year":"2019","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101340_bib0083","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7492","key":"10.1016\/j.ctarc.2026.101340_bib0084","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ctarc.2026.101340_bib0085","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"L\u00f3pez-Knowles","year":"2006","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0086","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"issue":"5835","key":"10.1016\/j.ctarc.2026.101340_bib0087","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1135394","article-title":"Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit","volume":"317","author":"Miled","year":"2007","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0088","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccr.2009.10.016","article-title":"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation","volume":"16","author":"Jaiswal","year":"2009","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0089","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms","volume":"105","author":"Zhao","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5857","key":"10.1016\/j.ctarc.2026.101340_bib0090","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1126\/science.1150799","article-title":"The structure of a human p110alpha\/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations","volume":"318","author":"Huang","year":"2007","journal-title":"Science"},{"issue":"3-4","key":"10.1016\/j.ctarc.2026.101340_bib0091","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-009-9198-3","article-title":"Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer","volume":"28","author":"Knowles","year":"2009","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0092","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/onc.2012.87","article-title":"PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs","volume":"32","author":"Ross","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101340_bib0093","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.ajpath.2023.07.001","article-title":"Urothelium-Specific Expression of Mutationally Activated Pik3ca Initiates Early Lesions of Noninvasive Bladder Cancer","volume":"193","author":"Shuman","year":"2023","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0094","doi-asserted-by":"crossref","first-page":"10531","DOI":"10.18632\/oncotarget.14453","article-title":"Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer","volume":"8","author":"Segovia","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0095","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0096","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.celrep.2014.05.012","article-title":"APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development","volume":"7","author":"Henderson","year":"2014","journal-title":"Cell Rep"},{"issue":"35","key":"10.1016\/j.ctarc.2026.101340_bib0097","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1073\/pnas.1009652107","article-title":"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha","volume":"107","author":"Sun","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101340_bib0098","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084411","article-title":"Identification of mutations in distinct regions of p85 alpha in urothelial cancer","volume":"8","author":"Ross","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101340_bib0099","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/0008-5472.CAN-09-3399","article-title":"The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling","volume":"70","author":"Taniguchi","year":"2010","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0100","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/s41594-021-00668-5","article-title":"The structural basis of PTEN regulation by multi-site phosphorylation","volume":"28","author":"Dempsey","year":"2021","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0101","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/biom9110713","article-title":"The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities","volume":"9","author":"Chang","year":"2019","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0102","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","article-title":"PTEN loss in the continuum of common cancers, rare syndromes and mouse models","volume":"11","author":"Hollander","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"5-6","key":"10.1016\/j.ctarc.2026.101340_bib0103","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.bjc.6690439","article-title":"Somatic mutation of PTEN in bladder carcinoma","volume":"80","author":"Aveyard","year":"1999","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0104","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.70105","article-title":"PTEN Deletions Are Associated With Tumor Progression But Unrelated to Patient Prognosis in Muscle-Invasive Urothelial Bladder Carcinomas: A Large Multi-Center Validation Study on 2710 Urothelial Bladder Carcinomas","volume":"65","author":"Kluth","year":"2026","journal-title":"Genes Chromosomes Cancer."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018583","article-title":"A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1","volume":"6","author":"Sj\u00f6dahl","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0106","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/mc.20420","article-title":"Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray","volume":"47","author":"Harris","year":"2008","journal-title":"Mol Carcinog"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101340_bib0107","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1158\/0008-5472.CAN-05-4627","article-title":"Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients","volume":"66","author":"Tsuruta","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0108","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2559.2011.03856.x","article-title":"Activation of the PI3K\/Akt\/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder","volume":"58","author":"Sun","year":"2011","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0109","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","article-title":"Cordon-Cardo C, Abate-Shen C. Inactivation of p53 and Pten promotes invasive bladder cancer","volume":"23","author":"Puzio-Kuter","year":"2009","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000085933","article-title":"Differential PTEN protein expression profiles in superficial versus invasive bladder cancers","volume":"75","author":"Koksal","year":"2005","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0111","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41388-019-1063-4","article-title":"Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer","volume":"39","author":"Osei-Amponsa","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0112","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2012.09.007","volume":"81","author":"Chaux","year":"2013","journal-title":"Urology"},{"issue":"27","key":"10.1016\/j.ctarc.2026.101340_bib0113","doi-asserted-by":"crossref","first-page":"14160","DOI":"10.1074\/jbc.M116.728980","article-title":"Molecular Features of Phosphatase and Tensin Homolog (PTEN) Regulation by C-terminal Phosphorylation","volume":"291","author":"Chen","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctarc.2026.101340_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215924","article-title":"Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal\/squamous-subtype muscle-invasive bladder cancer","volume":"550","author":"He","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctarc.2026.101340_bib0115","first-page":"1517","article-title":"Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine","volume":"14","author":"Coleman","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0116","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cancergencyto.2009.01.009","article-title":"AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma","volume":"191","author":"Zilberman","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0117","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/onc.2009.315","article-title":"AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K","volume":"29","author":"Askham","year":"2010","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.ctarc.2026.101340_bib0118","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2026.101340_bib0119","article-title":"PI3K\/Akt\/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1464-410X.2004.04574.x","article-title":"The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion","volume":"93","author":"Wu","year":"2004","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0121","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.humpath.2011.10.026","article-title":"Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer","volume":"43","author":"Juanpere","year":"2012","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0122","first-page":"329","article-title":"PI3K\/AKT pathway genetic alterations and dysregulation of expression in bladder cancer","volume":"24","author":"Kachrilas","year":"2019","journal-title":"J BUON"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0123","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.ju.0000058253.40352.60","article-title":"The tuberous sclerosis complex and its highly variable manifestations","volume":"169","author":"Lendvay","year":"2003","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0124","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/biom14091190","article-title":"Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets","volume":"14","author":"Conte","year":"2024","journal-title":"Biomolecules"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101340_bib0125","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/hmg\/ddn098","article-title":"Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms","volume":"17","author":"Pymar","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101340_bib0126","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1158\/1078-0432.CCR-12-1807","article-title":"Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis","volume":"18","author":"Hurst","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101340_bib0127","first-page":"7652","article-title":"Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder","volume":"63","author":"Knowles","year":"2003","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"Grabiner","year":"2014","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0129","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1074\/jbc.M112.399485","article-title":"Mutations in critical domains confer the human mTOR gene strong tumorigenicity","volume":"288","author":"Murugan","year":"2013","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0130","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081081","article-title":"Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0132","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.2353\/ajpath.2010.090872","article-title":"Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma","volume":"176","author":"Hansel","year":"2010","journal-title":"Am J Pathol"},{"issue":"11 Pt C","key":"10.1016\/j.ctarc.2026.101340_bib0133","article-title":"A comprehensive immunohistochemical and molecular approach to the PI3K\/AKT\/mTOR (phosphoinositide 3-kinase\/v-akt murine thymoma viral oncogene\/mammalian target of rapamycin) pathway in bladder urothelial carcinoma","volume":"110","author":"Korkolopoulou","year":"2012","journal-title":"BJU Int"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101340_bib0134","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1002\/cncr.25502","article-title":"Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy","volume":"116","author":"Schultz","year":"2010","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4111\/kju.2011.52.7.466","article-title":"Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study","volume":"52","author":"Park","year":"2011","journal-title":"Korean J Urol"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0136","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.juro.2014.08.106","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer","volume":"193","author":"Ferrari","year":"2015","journal-title":"J Urol"},{"issue":"35","key":"10.1016\/j.ctarc.2026.101340_bib0137","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1200\/JCO.2006.08.2073","article-title":"Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification","volume":"24","author":"Mitra","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0138","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/BLC-200373","article-title":"FGFR3 \u2013 a Central Player in Bladder Cancer Pathogenesis?","volume":"6","author":"Knowles","year":"2020","journal-title":"Bladder Cancer."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0139","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1242\/dmm.006874","article-title":"K-Ras and \u03b2-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder","volume":"4","author":"Ahmad","year":"2011","journal-title":"Dis Model Mech"},{"issue":"48","key":"10.1016\/j.ctarc.2026.101340_bib0140","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1038\/onc.2009.280","article-title":"Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner","volume":"28","author":"di Martino","year":"2009","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0141","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/path.4334","article-title":"Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice","volume":"233","author":"Foth","year":"2014","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0142","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI30062","article-title":"Hyperactivation of Ha-ras oncogene, but not Ink4a\/Arf deficiency, triggers bladder tumorigenesis","volume":"117","author":"Mo","year":"2007","journal-title":"J Clin Invest"},{"issue":"33","key":"10.1016\/j.ctarc.2026.101340_bib0143","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101340_bib0144","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mc.22125","article-title":"PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors","volume":"54","author":"Due\u00f1as","year":"2015","journal-title":"Mol Carcinog"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12672-024-01173-z","article-title":"The roles of FGFR3 and c-MYC in urothelial bladder cancer","volume":"15","author":"Bogale","year":"2024","journal-title":"Discov Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0146","first-page":"1226","article-title":"FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells","volume":"18","author":"Xie","year":"2019","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0147","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0148","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.eururo.2017.01.021","article-title":"A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma","volume":"71","author":"Wang","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0149","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","article-title":"Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398","volume":"16","author":"Datta","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3346\/jkms.2015.30.3.308","article-title":"P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model","volume":"30","author":"Chi","year":"2015","journal-title":"J Korean Med Sci"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101340_bib0151","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","article-title":"Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer","volume":"2","author":"Seager","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0152","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ajpath.2016.01.008","article-title":"Transforming Growth Factor-\u03b2 Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion","volume":"186","author":"Gupta","year":"2016","journal-title":"Am J Pathol"},{"issue":"40","key":"10.1016\/j.ctarc.2026.101340_bib0153","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1038\/sj.onc.1207599","article-title":"PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity","volume":"23","author":"Gildea","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016209","article-title":"Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder","volume":"6","author":"Shorning","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/onc.2010.399","article-title":"\u03b2-Catenin activation synergizes with PTEN loss to cause bladder cancer formation","volume":"30","author":"Ahmad","year":"2011","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0156","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-05-1986","article-title":"Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner","volume":"66","author":"Yoo","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101340_bib0157","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.15252\/emmm.201404402","article-title":"Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K","volume":"6","author":"Liu","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"7051","key":"10.1016\/j.ctarc.2026.101340_bib0158","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature03918","article-title":"Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0159","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1097-2765(01)00323-9","article-title":"Regulation of PTEN transcription by p53","volume":"8","author":"Stambolic","year":"2001","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(03)00021-7","article-title":"PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms","volume":"3","author":"Freeman","year":"2003","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101340_bib0161","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41388-025-03311-5","article-title":"PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations","volume":"44","author":"Hamada","year":"2025","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0162","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1158\/0008-5472.CAN-14-3067","article-title":"Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas","volume":"75","author":"He","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0163","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0164","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/his.12209","article-title":"PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer","volume":"63","author":"Cordes","year":"2013","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038863","article-title":"Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma","volume":"7","author":"Lindgren","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0166","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101340_bib0167","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101340_bib0168","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101340_bib0169","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-17-0033","article-title":"The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer","volume":"23","author":"Zeng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101340_bib0170","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4161\/cbt.21793","article-title":"Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells","volume":"13","author":"Dickstein","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0171","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/bjc.2014.534","article-title":"Mutant PIK3CA controls DUSP1-dependent ERK 1\/2 activity to confer response to AKT target therapy","volume":"111","author":"Sathe","year":"2014","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.ctarc.2026.101340_bib0172","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0173","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","article-title":"Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells","volume":"17","author":"Chiong","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0174","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.2013.505","article-title":"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K\/Akt activation","volume":"109","author":"Seront","year":"2013","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027509","article-title":"S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer","volume":"6","author":"Nawroth","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190854","article-title":"Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy","volume":"13","author":"Sathe","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0177","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.urolonc.2013.06.002","article-title":"The combination of an mTORc1\/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro","volume":"32","author":"Becker","year":"2014","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0178","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"VS","year":"2011","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0179","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3892\/ijo.2014.2505","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells","volume":"45","author":"Moon du","year":"2014","journal-title":"Int J Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101340_bib0180","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.3390\/ijms21082825","article-title":"Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0181","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101340_bib0182","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","article-title":"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers","volume":"23","author":"Seront","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0183","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12885-018-4059-5","article-title":"Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer","volume":"18","author":"Pulido","year":"2018","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101340_bib0184","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1002\/cncr.33071","article-title":"A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma","volume":"126","author":"McPherson","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101340_bib0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bju.13415","article-title":"Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma","volume":"118","author":"Seront","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.ctarc.2026.101340_bib0186","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2021.39.6_suppl.431","article-title":"Sapanisertib, a dual mTORC1\/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC)","volume":"39","author":"Kim","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0187","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102123","article-title":"Dual mTOR1\/2 Inhibitor Sapanisertib (FTH-003\/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study","volume":"22","author":"Bellmunt","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"6104","key":"10.1016\/j.ctarc.2026.101340_bib0188","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101340_bib0189","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41416-018-0261-0","article-title":"Everolimus and pazopanib (E\/P) benefit genomically selected patients with metastatic urothelial carcinoma","volume":"119","author":"Bellmunt","year":"2018","journal-title":"Br J Cancer"},{"issue":"29","key":"10.1016\/j.ctarc.2026.101340_bib0190","doi-asserted-by":"crossref","first-page":"11988","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Pourdehnad","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101340_bib0191","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hep.29183","article-title":"A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis","volume":"66","author":"Liu","year":"2017","journal-title":"Hepatology"},{"issue":"47","key":"10.1016\/j.ctarc.2026.101340_bib0192","doi-asserted-by":"crossref","first-page":"76374","DOI":"10.18632\/oncotarget.13062","article-title":"Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts","volume":"7","author":"Wei","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101340_bib0193","doi-asserted-by":"crossref","first-page":"e8163","DOI":"10.15252\/emmm.201708163","article-title":"An FGFR3\/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers","volume":"10","author":"Mahe","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ctarc.2026.101340_bib0194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00221","article-title":"Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations","volume":"3","author":"Hyman","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101340_bib0195","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101340_bib0196","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101340_bib0197","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002917","article-title":"Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer","volume":"9","author":"Zhu","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0198","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581556","article-title":"Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer","volume":"8","author":"Borcoman","year":"2019","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101340_bib0199","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:55:23Z","timestamp":1790913323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":199,"alternative-id":["S2468294226002510"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101340","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of the PI3K\/AKT\/mTOR signaling pathway in bladder cancer pathogenesis and its therapeutic significance","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101340"}}